1-20 of 80
Authors: Yoshiya Tanaka
Save search
Sort by
Journal Article

OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years

PDF
Kevin L Winthrop and others
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.012, https://doi.org/10.1093/rheumatology/keaf142.012
Published: 28 April 2025
Journal Article

P171 Bimekizumab maintained efficacy responses in patients with active psoriatic arthritis: up to 2-year results from two Phase 3 studies

PDF
Jessica A Walsh and others
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.208, https://doi.org/10.1093/rheumatology/keaf142.208
Published: 28 April 2025
Journal Article

Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial Get access

PDF
Ryu Watanabe and others
Rheumatology, keaf171, https://doi.org/10.1093/rheumatology/keaf171
Published: 26 March 2025
Journal Article

A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis

PDF
Hilde Jenssen Bjørkekjær and others
Rheumatology, keaf053, https://doi.org/10.1093/rheumatology/keaf053
Published: 29 January 2025
Journal Article

What is rheumatoid factor? From screening to personalized management

PDF
Yoshiya Tanaka
Rheumatology, Volume 64, Issue Supplement_2, March 2025, Pages ii9–ii14, https://doi.org/10.1093/rheumatology/keaf003
Published: 10 January 2025
Journal Article

Association of lupus low disease activity state and remission with reduced organ damage and flare in systemic lupus erythematosus patients with high disease activity: a multi-national, longitudinal cohort study

PDF
Rangi Kandane-Rathnayake and others
Rheumatology, Volume 64, Issue 5, May 2025, Pages 2741–2748, https://doi.org/10.1093/rheumatology/keae631
Published: 04 December 2024
Journal Article

Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry Get access

PDF
Hiroki Kobayashi and others
Rheumatology, Volume 64, Issue 5, May 2025, Pages 2403–2410, https://doi.org/10.1093/rheumatology/keae598
Published: 05 November 2024
Journal Article

Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry Get access

PDF
Hidenori Sakai and others
Rheumatology, Volume 64, Issue 4, April 2025, Pages 1930–1939, https://doi.org/10.1093/rheumatology/keae495
Published: 17 September 2024
Journal Article

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis

PDF
Josef S Smolen and others
Rheumatology, Volume 63, Issue 11, November 2024, Pages 3015–3024, https://doi.org/10.1093/rheumatology/keae435
Published: 02 September 2024
Journal Article

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry Get access

PDF
Yusuke Miyazaki and others
Rheumatology, Volume 64, Issue 4, April 2025, Pages 1627–1636, https://doi.org/10.1093/rheumatology/keae334
Published: 18 June 2024
Journal Article

P117 Efficacy of filgotinib in patients with rheumatoid arthritis: Week 156 results from a long-term extension study

PDF
Maya H Buch and others
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.158, https://doi.org/10.1093/rheumatology/keae163.158
Published: 24 April 2024
Journal Article

E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study

PDF
William R Tillett and others
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.296, https://doi.org/10.1093/rheumatology/keae163.296
Published: 24 April 2024
Journal Article

E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study

PDF
William R Tillett and others
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.294, https://doi.org/10.1093/rheumatology/keae163.294
Published: 24 April 2024
Journal Article

P106 Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial.

PDF
Josef S Smolen and others
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.147, https://doi.org/10.1093/rheumatology/keae163.147
Published: 24 April 2024
Journal Article

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study

PDF
Koshiro Sonomoto and others
Rheumatology, Volume 63, Issue 8, August 2024, Pages 2239–2248, https://doi.org/10.1093/rheumatology/kead579
Published: 02 November 2023
Journal Article

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry

PDF
Yusuke Miyazaki and others
Rheumatology, Volume 63, Issue 9, September 2024, Pages 2345–2354, https://doi.org/10.1093/rheumatology/kead568
Published: 02 November 2023
Journal Article

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

PDF
Peter C Taylor and others
Rheumatology, Volume 63, Issue 2, February 2024, Pages 298–308, https://doi.org/10.1093/rheumatology/kead448
Published: 25 August 2023
Journal Article
EDITOR'S CHOICE

Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease

PDF
Yasuyuki Todoroki and others
Rheumatology, Volume 63, Issue 4, April 2024, Pages 1068–1075, https://doi.org/10.1093/rheumatology/kead341
Published: 08 July 2023
Journal Article

SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring

PDF
Ai Li Yeo and others
Rheumatology, Volume 63, Issue 2, February 2024, Pages 525–533, https://doi.org/10.1093/rheumatology/kead231
Published: 19 May 2023
Journal Article

OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions

PDF
Maya H Buch and others
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.006, https://doi.org/10.1093/rheumatology/kead104.006
Published: 24 April 2023